Home Medicine FDA Removes Partially Confidentiality from Viaskin Peanut Patch to Treat Peanut Allergy

FDA Removes Partially Confidentiality from Viaskin Peanut Patch to Treat Peanut Allergy

21
0


DBV Technologies announced that the Food and Drug Administration (FDA) has lifted the partial clinical hold from a Phase 3 clinical trial for Viaskin™ Peanut. A “partial clinical hold” is a delay or a suspension of part of a clinical study. Viaskin Peanut (a skin patch) is a novel treatment being tested for peanut allergy treatment. Phase 3 of VITESSE, the Viaskin Peanut Immunotherapy Trial To Evaluate Safety Simplicity, Efficacy and Effectiveness, is designed to examine the modified…



Continue reading…

Previous articleWhy did Medicare spending growth slow down over the past decade, and what can we do to reverse this trend?
Next articleAir Fryer Okra With Remoulade